Skip to Content
Merck

LRRK2 mediates tubulation and vesicle sorting from lysosomes.

Science advances (2020-11-13)
Luis Bonet-Ponce, Alexandra Beilina, Chad D Williamson, Eric Lindberg, Jillian H Kluss, Sara Saez-Atienzar, Natalie Landeck, Ravindran Kumaran, Adamantios Mamais, Christopher K E Bleck, Yan Li, Mark R Cookson
ABSTRACT

Genetic variation around the LRRK2 gene affects risk of both familial and sporadic Parkinson's disease (PD). However, the biological functions of LRRK2 remain incompletely understood. Here, we report that LRRK2 is recruited to lysosomes after exposure of cells to the lysosome membrane-rupturing agent LLOME. Using an unbiased proteomic screen, we identified the motor adaptor protein JIP4 as an LRRK2 partner at the lysosomal membrane. LRRK2 can recruit JIP4 to lysosomes in a kinase-dependent manner via the phosphorylation of RAB35 and RAB10. Using super-resolution live-cell imaging microscopy and FIB-SEM, we demonstrate that JIP4 promotes the formation of LAMP1-negative tubules that release membranous content from lysosomes. Thus, we describe a new process orchestrated by LRRK2, which we name LYTL (LYsosomal Tubulation/sorting driven by LRRK2), by which lysosomal tubulation is used to release vesicles from lysosomes. Given the central role of the lysosome in PD, LYTL is likely to be disease relevant.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human SPAG9
Sigma-Aldrich
Nocodazole, ≥99% (TLC), powder
Sigma-Aldrich
Monoclonal ANTI-FLAG® M2 antibody produced in mouse, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)
Sigma-Aldrich
Leu-Leu methyl ester hydrobromide, ≥97% (TLC)
Roche
Anti-GFP, from mouse IgG1κ (clones 7.1 and 13.1)
Supelco
Sodium carbonate concentrate, 0.1 M Na2CO3 in water, eluent concentrate for IC